Our unwavering commitment to our patients requires that we act responsibly on all fronts. Our actions are for the benefit of the patients we serve around the world, our company, our employees, our shareholders and our communities.
Celgene is now part of Bristol Myers Squibb creating a leading biopharma company positioned to help address the needs of patients with serious diseases. Funding requests may continue to be submitted via the current BMS processes until further notice.
During this transition period, we will jointly review all requests as a team to avoid duplication of funding.
In addition, we are currently updating our FAQs, which will be updated on or about 12/15/2019. Any questions can be submitted to firstname.lastname@example.org
We continue the quest to increase access to medicines for those in need through research and development, our partnership with patients, advocacy groups, healthcare providers, industry, governments and NGOs, and our focus on healthcare infrastructure, product quality and safety.